Navigation Links
GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
Date:1/3/2008

Compound 642444 and Compound 685698 advance in clinical development for the

treatment of asthma

LONDON, PHILADELPHIA and SAN FRANCISCO, Jan. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) today announced the start of large Phase 2b asthma dose-optimization studies with both the lead inhaled corticosteroid (ICS) GW685698 ('698) and the lead long-acting beta agonist (LABA) GW642444 ('444) assets in the 'Horizon' program to develop a next-generation combination product.

GSK began enrolling patients with mild to severe asthma in the '698 Phase 2b clinical program on 21st December 2007 and began enrolling patients with persistent asthma in the '444 Phase 2b clinical program on 29th December 2007. These clinical programs will determine the most effective doses to be taken into Phase 3 combination studies. The Phase 2b COPD program with '444 is also on schedule to commence in 1H 2008.

Darrell Baker, SVP GSK Respiratory Medicines Development Centre said, "The program is progressing well and we are delighted to have two very strong assets to progress into our large Phase 2b studies." He continued, "We have seen encouraging results in previous studies and have confidence in our ongoing program. Both asthma and COPD are serious, debilitating diseases where there remains a considerable unmet need. We believe through this program we will introduce a meaningful option for the treatment of patients with these conditions."

"We are very p
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
2. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
3. GlaxoSmithKline Accelerates Review of Exelixis XL880
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
8. FASgen Announces a New Discovery in Obesity Research
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces New Discovery for Treatment of Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 According ... Development Market by Product (Equipment, Media and Reagents), by ... & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) ... by MarketsandMarkets, analyzes and studies the major market ... Browse 114 market data tables and 64 figures ...
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Diclofenac Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The diclofenac ...
(Date:9/22/2014)... , Sept. 22, 2014 CytRx Corporation ... development company specializing in oncology, today announced that study ... clinical trials of aldoxorubicin, a pivotal global Phase 3 ... a global Phase 2b clinical trial in small cell ... for Medical Oncology (ESMO) 2014 Congress being held September ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4Global and Chinese Diclofenac Industry Report 2014 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
(Date:9/22/2014)... 22, 2014 Oregon Governor John ... as “Oregon Chiropractic Health and Wellness Month.” , ... (UWS) celebrates 110 years of leadership in educating ... was the first educational institution offering a doctor ... expanded over the past 110 years and now ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Respiratory care market occupies a significant presence in ... the most widespread healthcare problems globally. Key factors ... unhealthy lifestyle habits such as smoking; increasing levels ... COPD; and expanding base of aging population vulnerable ...
(Date:9/22/2014)... The Spa Standard, announced today that Jenny ... in developing content and courses for their online social ... 15 years of experience in massage therapy, esthetics, day ... companies including Orient Express Hotels and the Capella Hotel ... Jenny gained extensive industry insight through planning, staffing, training ...
(Date:9/22/2014)... 22, 2014 The American Association for Thoracic ... the prevention and treatment of perioperative and postoperative ... procedures. The guidelines are published in The ... "These guidelines have the potential to prevent the ... who undergo lung surgery in the United States ...
(Date:9/22/2014)... can enhance the ability of the bacterium Streptococcus ... to research published ahead of print in the journal ... study, the investigators infected mice with either influenza alone, ... the populations of bacteria and virus over time. They ... infection. , Influenza infection enhanced the bacterium,s ability ...
Breaking Medicine News(10 mins):Health News:Oregon Governor Proclaims October as “Chiropractic Month” – UWS Brought Chiropractic Health Care to Oregon in 1904 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 4Health News:The Spa Standard Appoints Vice-President of Content and Course Development 2Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 2Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 3Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 4Health News:Influenza A potentiates pneumococcal co-infection: New details emerge 2
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
... ... custom stress balls has started 2010 with two record months which points to an economic ... ... balls has started 2010 with two record months which points to an economic upturn ...
... ctp ... this means for leadership and how it is redefining our understanding of soft skills. ... – all leading to better organisations and higher returns on human investment. , ... (PRWEB) March 2, 2010 ...
... Clinically Relevant Technologies ... management guidelines with the release of new medical iPhone app. , ... (PRWEB) March 2, 2010 -- Clinically Relevant Technologies released a new ... care gap. The release comes on the heels of a study published last month in ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
... Introduction of the Selenia full ... beginning of a new era in ... of elegance and innovation combines the ... with sophisticated information management capabilities to ...
... The Stellate Harmonie workstation is a ... processing loads, high quality video capability, and ... recording and review functions A framework that ... and archiving of data A centralized database ...
... features is the PupilFit software which automatically ... the pupil images, producing accurate, repeatable measurements ... circle is shown as a dotted line ... measurement ismeaningful, and not just a number ...
Dual-sided, Interhemispheric Grid Electrode with 16 Contact Leads; Cortical Grid Electrode with 16 Contact Leads; Pediatric Grid Electrode with Flex Connector, 0.5 cm spacing...
Medicine Products: